Alexandra Haase

Mar 28, 2024 | nature.com | Kevin Ullmann |Felix Manstein |Lika Drakhlis |Ulrich Martin |Nils Kriedemann |Alexandra Haase

AbstractA promising cell-therapy approach for heart failure aims at differentiating human pluripotent stem cells (hPSCs) into functional cardiomyocytes (CMs) in vitro to replace the disease-induced loss of patients’ heart muscle cells in vivo. But many challenges remain for the routine clinical application of hPSC-derived CMs (hPSC-CMs), including good manufacturing practice (GMP)-compliant production strategies.